BioAge Labs will host an R&D Day webcast on May 8, 2026, to present Phase 1 clinical data for BGE-102, a novel oral NLRP3 inflammasome inhibitor. The drug targets inflammation linked to atherosclerotic cardiovascular disease and retinal diseases like diabetic macular edema. The event will feature presentations by BioAge leadership and four medical experts discussing the drug's mechanism and therapeutic potential. Phase 2 data for cardiovascular risk is expected in the second half of 2026, with retinal disease data anticipated in mid-2027.
Girard Sharp LLP is investigating potential securities claims for former Discover investors who received Capital One shares after Capital One acquired Discover in May 2025. Since the merger, Capital One's stock price has declined, leading to possible...
Sunshine Silver, a mining and refining company based in Idaho, is preparing for a $2.32 billion initial public offering on the New York Stock Exchange. The company aims to raise up to $330 million by selling 20 million shares priced between $13.50 an...
Agomab Therapeutics NV held its Annual General Meeting on May 26, 2026, where shareholders approved all agenda items. This included the approval of the 2025 financial statements, discharge of board members and auditors for their duties, and the reapp...
The global Carbon Capture, Utilization, and Storage (CCUS) absorption market is projected to expand significantly, growing from $1.58 billion in 2025 to $12.56 billion by 2035 at a CAGR of 23.06%. This growth is fueled by increased government initiat...
The global resin market is projected to grow from $667.16 billion in 2025 to $1.14 trillion by 2035, at a CAGR of 5.06%. Growth is fueled by advancements in resin technology improving thermal stability and strength, expanding use in aerospace, electr...
